Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 3:20 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 11,257 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Newborn Clear all

Conditions: Limb Deformities Congenital, Limb Deformities Nos (Acquired), Deformity of Bone
Interventions: DePuy Synthes MAXFRAMETM system; Device
Lead sponsor: AO Innovation Translation Center; Other
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Atopic Dermatitis
Interventions: FB825, Placebo; Drug
Lead sponsor: Oneness Biotech Co., Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 6
States / cities: Fountain Valley, California • Fremont, California • Los Angeles, California + 3 more

Conditions: Sickle Cell Disease, Sickle Beta Zero Thalassemia, Sickle B+ Thalassemia, Sickle Cell Hemoglobin C
Interventions: MED-Go App; Behavioral
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 12 Years to 21 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cystic Fibrosis
Interventions: Aeroquin, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 12 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 95
States / cities: Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 82 more

Conditions: Cystic Fibrosis
Interventions: Sildenafil 40mg oral capsule, Placebo Oral capsule; Drug
Lead sponsor: National Jewish Health; Other
Eligibility: 9 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 2
States / cities: Denver, Colorado • Augusta, Georgia

Conditions: Congenital Diaphragmatic Hernia, Pulmonary Hypoplasia, Pulmonary; Hypertension
Interventions: Fetal Tracheal Occlusion; Device
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Retinopathy of Prematurity
Interventions: aflibercept, laser photocoagulation; Drug · Procedure
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: Not listed
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 27
States / cities: Phoenix, Arizona • La Jolla, California • Loma Linda, California + 21 more

Conditions: Huntington's Disease
Interventions: coenzyme Q10, placebo; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 16 Years and older
Enrollment: 609 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 41
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Fayetteville, Arkansas + 37 more

Conditions: Arteriovenous Malformation
Interventions: Not listed
Lead sponsor: St. Joseph's Hospital and Medical Center, Phoenix; Other
Eligibility: 6 Years to 60 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Musculoskeletal Complications
Interventions: levocarnitine, placebo, questionnaire administration; Dietary Supplement · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Stanford, California

Conditions: Gout
Interventions: Lesinurad, Placebo, Allopurinol; Drug
Lead sponsor: Ardea Biosciences, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 610 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 88
States / cities: Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 76 more

Conditions: Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts
Interventions: decitabine, idarubicin, cytarabine; Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Atopic Dermatitis
Interventions: Pimecrolimus Cream, 1%, Elidel® (pimecrolimus) Cream, Placebo of Pimecrolimus Cream, 1%; Drug
Lead sponsor: Glenmark Pharmaceuticals Ltd. India; Industry
Eligibility: 12 Years and older
Enrollment: 755 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 27
States / cities: Hot Springs, Arkansas • Little Rock, Arkansas • Anaheim, California + 19 more

Conditions: Pompe Disease
Interventions: BMN 701; Biological
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 13 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 3
States / cities: La Jolla, California • Gainesville, Florida • Kansas City, Kansas

Conditions: Tracheoesophageal Fistula, Esophageal Atresia, Laryngeal Cleft, Tracheal Stenosis, Bronchial Stenosis, Esophageal Bronchus, Congenital High Airway Obstruction Syndrome
Interventions: Not listed
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Not listed
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Huntington Disease
Interventions: Time-Restricted Eating Diet; Behavioral
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 21 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions: anti-thymocyte globulin, cyclosporine, fludarabine phosphate, melphalan, methylprednisolone, mycophenolate mofetil, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, syngeneic bone marrow transplantation; Biological · Drug · Procedure
Lead sponsor: Herbert Irving Comprehensive Cancer Center; Other
Eligibility: 1 Year to 80 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 1
States / cities: New York, New York

Conditions: Pseudomonas Infection
Interventions: Ciprofloxacin (Cipro, BAYQ3939); Drug
Lead sponsor: Bayer; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 4
States / cities: Atlanta, Georgia • Baltimore, Maryland • Boston, Massachusetts + 1 more

Conditions: Retinopathy of Prematurity
Interventions: Bevacizumab; Drug
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: Up to 6 Months
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 11
States / cities: Atlanta, Georgia • Indianapolis, Indiana • Baltimore, Maryland + 8 more

Conditions: Facioscapulohumeral Muscular Dystrophy
Interventions: Not listed
Lead sponsor: Cooperative International Neuromuscular Research Group; Network
Eligibility: Not listed
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 7
States / cities: Sacramento, California • Washington D.C., District of Columbia • Minneapolis, Minnesota + 4 more

Conditions: Retinopathy of Prematurity, Retinal Detachment, Blindness
Interventions: ACULAR, REFRESH TEARS, placebo; Drug
Lead sponsor: University of South Alabama; Other
Eligibility: 10 Days to 15 Days
Enrollment: 83 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Mobile, Alabama

Conditions: Idiopathic Pulmonary Arterial Hypertension, Cardiomyopathy
Interventions: Nitric Oxide for inhalation, Oxygen, Nitric Oxide plus Oxygen; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 4 Weeks to 18 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 8
States / cities: Stanford, California • Denver, Colorado • Boston, Massachusetts + 5 more

Conditions: Mucopolysaccharidosis Type IIIB, MPS IIIB (Sanfilippo B Syndrome)
Interventions: Tralesinidase alfa (TA); Drug
Lead sponsor: Spruce Biosciences; Industry
Eligibility: 12 Months and older
U.S. locations: 1
States / cities: Oakland, California

Conditions: Congenital Heart Disease
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

Prospective Multicenter Registry for Use of the MAXFRAME™ Multiaxial Correction System

Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis

An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell Disease

MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis

Sildenafil Exercise: Role of PDE5 Inhibition

Feto-Endoscopic Tracheal Occlusion (FETO) for Severe Congenital Diaphragmatic Hernia

Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity

Coenzyme Q10 in Huntington's Disease (HD)

Genetics of Arteriovenous Malformations

Levocarnitine in Treating Patients With Vismodegib-Associated Muscle Spasms

Combining Lesinurad With Allopurinol in Inadequate Responders

Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS

Study of Generic Pimecrolimus Cream, 1% in the Treatment of Mild to Moderate Atopic Dermatitis

Safety/Tolerability/Pharmacokinetic (PK)/Pharmacodynamics (PD) Study of BMN701 in Patients With Late-Onset Pompe Disease

Phenotypic and Genetic Assessment of Tracheal and Esophageal Birth Defects in Patients

Time-Restricted Eating in Huntington's Disease: A Clinical Pilot Study

Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders

Cipro Inhaler for Cystic Fibrosis Children Ages 6-12

Phase 1 Trial of Bevacizumab Treatment for Severe Retinopathy of Prematurity

A Multicenter Collaborative Study on the Clinical Features, Expression Profiling, and Quality of Life of Infantile Onset FSHD

Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity

Comparison of Inhaled Nitric Oxide and Oxygen in Participants Reactivity During Acute Pulmonary Vasodilator Testing

Early Access Treatment With Tralesinidase Alfa in Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B)

A Study of Pregnancy Outcomes in Congenital Heart Disease